Navigation Links
UC Irvine study of leaping toads reveals muscle-protecting mechanism

Irvine, Calif., Dec. 19, 2012 Most people are impressed by how a toad jumps. UC Irvine biologist Emanuel Azizi is more impressed by how one lands.

An assistant professor of ecology & evolutionary biology who specializes in muscle physiology and biomechanics, Azizi found that nature's favorite leapers possess a neuromuscular response that's specific to the intensity of a landing a mechanism that protects muscles from injury upon impact.

The research is helping reveal how the nervous system modulates motor control patterns involved with jumping and landing. Azizi's findings on the underlying function of muscle control, he said, could one day improve rehabilitation programs for people with neuromuscular deficiencies.

In all vertebrates from toads to humans muscles contract to provide jumping power. Landing, however, requires that muscles stretch to dissipate energy and slow the body. But if muscles become overstretched during landing, injury can occur.

For a study appearing online today in Biology Letters, Azizi and UC Irvine graduate student Emily Abbott measured toads' muscular responses to leaps of different lengths. They discovered that during landing, toads' muscles adapt to the varying intensity of impact. As the creatures hop over longer distances, their landing muscles increasingly shorten in anticipation of larger impacts.

This pattern indicates that rapid and coordinated responses of the nervous system can act to protect muscles from injury, said Azizi, who added that future efforts will be aimed at understanding what sensory information is used to modulate these responses.

"Toads are ideal for studying jumping and landing because they're so good at it," he noted. "This work is providing the basic science on how muscles respond during high-impact behaviors like landing or falling."

Contact: Tom Vasich
University of California - Irvine

Page: 1

Related biology news :

1. State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts
2. NTU study finds ways to prevent muscle loss, obesity and diabetes
3. Hass Avocado Board study published in Food & Function journal
4. Univ. of MD School of Medicine to study drug-resistant malaria in Myanmar
5. Study offers insights into role of muscle weakness in Down syndrome
6. University of Tennessee study predicts extreme climate in Eastern US
7. New menhaden study will help identify balance between fishing and preserving Bay forage fish
8. Study uncovers mechanism used by BRCA1 to suppress tumors
9. Penn Study shows resistance to cocaine addiction may be passed down from father to son
10. Study confirms prognostic value of new IASLC/ATS/ERS adenocarcinoma sub-classification
11. Study shows immunohistochemistry is reliable screening tool for ALK rearrangement
Post Your Comments:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
Breaking Biology Technology: